C. S. Lam

发表

Effects of Dapagliflozin in Patients in Asia

P. Jhund, M. Vaduganathan, M. Kitakaze, 2023, JACC: Asia.

Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.

A. Voors, C. McMullan, C. Westerhout, 2024, European journal of heart failure.

Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission

G. Filippatos, J. Čelutkienė, A. Voors, 2023, JAMA cardiology.

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

P. Jhund, M. Vaduganathan, S. Inzucchi, 2024, European journal of heart failure.

Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER.

P. Jhund, M. Vaduganathan, S. Inzucchi, 2023, Journal of cardiac failure.

Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial

P. Jhund, M. Vaduganathan, D. Lindholm, 2023, European journal of heart failure.

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

J. Čelutkienė, O. Chioncel, H. Burri, 2024, European journal of heart failure.

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.

P. Jhund, M. Vaduganathan, F. Martinez, 2024, European journal of heart failure.

Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study

T. Biering-Sørensen, A. Shah, M. Minamisawa, 2024, European journal of heart failure.

Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.

P. Jhund, M. Vaduganathan, B. Claggett, 2024, JAMA cardiology.